Literature DB >> 23076427

Syndrome of transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis (HaNDL): a pediatric case report.

Daniel Gonçalves1, Joana Meireles, Ruben Rocha, Mafalda Sampaio, Miguel Leão.   

Abstract

The syndrome of transient headache and neurologic deficits associated with cerebrospinal fluid lymphocytosis (HaNDL) is characterized by 1 or more episodes of severe headache, transient neurologic deficits, and lymphocytic pleocytosis in the cerebrospinal fluid. It is a benign and self limited disorder seldom reported in pediatric age. We report the case of a 14-year-old girl who suffered from 2 episodes of headache with transient focal neurologic deficits and pleocytosis consistent with the syndrome of HaNDL. This entity should be taken into account as a differential diagnosis in otherwise healthy children presenting with recurrent headache and acute neurologic deficits. Repeated use of invasive and expensive laboratory and imaging investigations can be avoided when the diagnosis of the syndrome of HaNDL is correctly established.

Entities:  

Keywords:  HaNDL; headache; pleocytosis

Mesh:

Year:  2012        PMID: 23076427     DOI: 10.1177/0883073812462063

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  3 in total

Review 1.  HaNDL syndrome in a 14-year-old girl.

Authors:  Elena Rivero-Sanz; Leticia Pias-Peleteiro; Veronica Gonzalez-Alvarez
Journal:  BMJ Case Rep       Date:  2016-01-14

2.  HaNDL with bilateral central venous occlusions.

Authors:  Wendy Wang; Heather G Mack; Richard Stawell; Owen White; John Waterston
Journal:  BMJ Neurol Open       Date:  2020-06-02

Review 3.  HaNDL syndrome: a reversible cerebral vasoconstriction triggered by an infection? A case report and a case-based review.

Authors:  Giuseppe Fiamingo; Isabella Canavero; Matteo Gastaldi; Elisa Coloberti; Gabriele Buongarzone; Natascia Ghiotto; Ana Bacila; Alfredo Costa; Sabrina Ravaglia
Journal:  Eur J Med Res       Date:  2022-10-08       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.